Pathological regression of primary tumour and metastatic lymph nodes following chemotherapy in resectable OG cancer: pooled analysis of two trials

A. Athauda, M. Nankivell, R. Langer, S. Pritchard, R.E. Langley, K. von Loga, N. Starling, I. Chau, D. Cunningham*, H.I. Grabsch*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

BackgroundNo definitive largescale data exist evaluating the role of pathologically defined regression changes within the primary tumour and lymph nodes (LN) of resected oesophagogastric (OG) adenocarcinoma following neoadjuvant chemotherapy and the impact on survival.MethodsData and samples from two large prospective randomised trials (UK MRC OE05 and ST03) were pooled. Stained slides were available for central pathology review from 1619 patients. Mandard tumour regression grade (TRG) and regression of tumour within LNs (LNR: scored as present/absent) were assessed and correlated with overall survival (OS) using a Cox regression model. An exploratory analysis to define subgroups with distinct prognoses was conducted using a classification and regression tree (CART) analysis.ResultsNeither trial demonstrated a relationship between TRG score and the presence or absence of LNR. In univariable analysis, lower TRG, lower ypN stage, lower ypT stage, presence of LNR, presence of well/moderate tumour differentiation, and absence of tumour at resection margin were all associated with better OS. However, the multivariable analysis demonstrated that only ypN, ypT, grade of differentiation and resection margin (R0) were independent indicators of prognosis. Exploratory CART analysis identified six subgroups with 3-year OS ranging from 83% to 22%; with ypN stage being the most important single prognostic variable.ConclusionsPathological LN stage within the resection specimen was the single most important determiner of survival. Our results suggest that the assessment of regression changes within the primary tumour or LNs may not be necessary to define the prognosis further.
Original languageEnglish
Pages (from-to)2036-2043
Number of pages8
JournalBritish Journal of Cancer
Volume128
Issue number11
Early online date1 Mar 2023
DOIs
Publication statusPublished - 15 Jun 2023

Keywords

  • PERIOPERATIVE CHEMOTHERAPY
  • OPEN-LABEL
  • NEOADJUVANT
  • ESOPHAGEAL
  • MULTICENTER
  • GRADE

Cite this